Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Chapter 4

Demyelination in multiple sclerosis

CATHERINE LUBETZKI* AND BRUNO STANKOFF
Centre de Recherche de l’Institut du Cerveau et de la Moelle Épinière, Salpêtrière Hospital, UMR S975, Paris, France

MECHANISMS OF DEMYELINATION IN MULTIPLE SCLEROSIS

Demyelination as a consequence of inflammation

THE ROLE OF ADAPTIVE IMMUNITY

Multiple sclerosis (MS) is generally considered as an autoimmune disease, in which autoreactive T cells enter the central nervous system (CNS) from the peripheral circulation and induce an inflammatory cascade resulting in demyelination and axonal loss. An extraordinary amount of literature has been accumulated since the initial experiment of Rivers and Schwentker in 1935 (see review by Sriram and Steiner, 2005) concerning the similarities and the dissimilarities between MS and its autoimmune model, experimental autoimmune encephalomyelitis (EAE). Because this animal model could be induced by passive transfer of CD4⁺ antimyelin lymphocytes, these cells have long been considered as the _primum movens_ of the demyelinating process in the CNS of MS patients. The most common hypothesis, therefore, suggests that CD4⁺ T-helper cells recognize their cognate myelin antigen in the context of major histocompatibility complex (MHC) class II-bearing antigen-presenting cells (APCs), with the putative APCs being either dendritic cells at the blood–brain barrier or microglial cells (Greter et al., 2005). Once entered into the brain, CD4⁺ T cells may proliferate and liberate myelinotoxic cytokines, such as interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α). However, increasing evidence now suggests that, in MS, the contribution of such T-helper cells is less prominent than previously thought, and that macrophages, CD8⁺ T cells and B cells are major component of the inflammatory infiltrate into the lesions of both EAE and MS (Traugott et al., 1983; Hauser et al., 1986).

Moreover the deleterious impact of TNF-α and IFN-γ on myelin in MS lesions has been contested (Lenercept Multiple Sclerosis Study Group, 1999; Lassmann, 2004). By contrast, there is growing evidence suggesting that cytotoxic CD8⁺ T cells may play a crucial role in the demyelination. Oligodendrocyte and/or myelin antigens can be recognized by CD8⁺ T cells due to their potential for MHC class I expression under inflammatory or stress conditions (Redwine et al., 2001; Hofberger et al., 2004). Also, CD8⁺ T cells in the blood, cerebrospinal fluid (CSF), and the lesions of MS patients have a more restricted expression of T-cell receptors than CD4⁺ cells, consistent with a primary role in an antigen-restricted inflammatory response (Babbe et al., 2000; Jacobsen et al., 2002; Skulina et al., 2004). These cells are present in close proximity to the myelin membranes, suggesting a role in tissue damage (Neumann et al., 2002).

Corroborating this hypothesis, a severe model of EAE was induced by adoptive transfer of anti-myelin basic protein (MBP) CD8⁺ T cells. This model has some interesting similarities with MS: it is characterized by perivascular inflammatory infiltrates and demyelination in the white matter, together with involvement of the gray matter and cortex; ischemic or cytotoxic injury is noted, with the presence of degenerative, apoptotic, and necrotic cells; it is improved by neutralizing antibodies to IFN-γ but not to TNF-α (Huseby et al., 2001). However, this effect was not specific to MBP antigens, as myelin oligodendrocyte glycoprotein (MOG) 35–55 cytotoxic T cells could also produce a severe disease in mice (Sun et al., 2001). Taken together, these data suggest that cytotoxic CD8⁺ cells might represent a major player in MS myelin injury.
It is now also well accepted that the T cells are not the only players in inducing MS lesions and demyelination, and B lymphocytes have emerged as critical actors in MS pathophysiology. This has been strongly suggested by the results of therapeutic trials showing a drastic effect on lesion formation and relapses using monoclonal antibodies against B-lymphocyte antigens, mainly CD20 (Hauser et al., 2008; Kappos et al., 2011), and by the negative results obtained using ustekinumab, a monoclonal antibody specifically targeting T lymphocytes, both TH1 and TH7 (Segal et al., 2008). Interestingly, most of the monoclonal antibodies that have been shown to be effective in MS (anti-VLA4, anti-CD52, anti-CD20) all have an effect on B-cell populations. This pathogenic role of B cells in lesion formation and demyelination does not seem to be restricted to the synthesis of antibodies by plasma cells, as most of the therapeutic benefits were independent of antibodies levels, but most convincingly implies a regulatory role on T-cell function as B cells are also professional APCs (Disanto et al., 2012).

The Role of Innate Immunity
To the extent that cell-mediated immunity is involved in demyelination in MS, competent APCs are an absolute requirement (Prat and Antel, 2005). Therefore innate immunity may play a key role in the demyelinating cascade by acting on the development and maintenance of inflammatory lesions. In the CNS putative APCs are microglial or dendritic cells. Whether these cells only trigger the inflammatory reaction or whether they could directly induce demyelination in MS remains an open question. In this context, a potentially primary role for innate autoimmunity in inflammatory demyelination has been proposed recently. Thus, activation of APCs through aberrant activation of Toll-like receptors could trigger and orchestrate an adaptive immune response to host antigens (Beutler, 2004; Prinz et al., 2006). However, in contrast to this proinflammatory role, activation of microglial cells and macrophages could also favor myelin repair, through their capacity to remove debris (David and Lacroix, 2003; Kotter et al., 2005). Recent data have emphasized that these cells could also modulate oligodendrogenesis (Butovsky et al., 2006).

Are Antibodies Involved in the Demyelinating Process?
A hallmark of MS is the persistence of intrathecal immunoglobulin production. However, the majority of these antibodies do not seem to be specific to neural targets, and there is no proven correlation between synthesis of oligoclonal immunoglobulin G (IgG) and disease progression (Walsh and Tourtellotte, 1986). Nevertheless, vesicular disruption of myelin seen in highly active MS lesions was found to be associated with anti-MOG and MBP antibodies, suggesting that demyelination might be causally related to the deposition of antigen-specific autoantibodies (Genain et al., 1999). Such antibodies could produce demyelination by several effector mechanisms, such as antibody-dependent cell-mediated cytotoxicity, release of inflammatory mediators through stimulation of Fc receptors on natural killer cells, macrophages, or mast cells, opsonization of myelin, or complement activation (Archeols and Hartung, 2000). Accordingly, macrophages engaged in demyelination have shown capping of surface IgG located in the cleft between the clathrin-coated pit and the associated myelin debris, suggesting a specific antibody-mediated process (Prineas and Graham, 1981). The deposition of antibodies on oligodendrocytes was described as a characteristic of common lesion subtypes (Lucchinetti et al., 2000), but the specificity of such deposition has been challenged, as several other pathologic conditions have shown a similar pattern (Barnett et al., 2009).

Experimentally, it is well known that demyelinating activity in the MOG-induced EAE is increased by the existence of specific anti-MOG antibodies (Linnington et al., 1988), especially when these antibodies recognize the native configuration (which is glycosylated) of MOG (Lalive et al., 2006). Such antibodies, as well as some MBP antibodies, have been detected in the serum of patients with clinically isolated syndromes and relapsing-remitting MS (Berger et al., 2003; Gaertner et al., 2004; Lalive et al., 2006). Although some studies did not reproduce these results (Lampasona et al., 2004; Mantegazza et al., 2004), high serum IgG titers to native MOG were detected in 40% of children with clinically isolated syndrome or acute disseminated encephalomyelitis, suggesting that in this subgroup MOG might be a target of the humoral immune response (Brilot et al., 2009).

However the influence of such antemyelin antibodies on demyelination, as well as their prognostic value, needs further investigation. Interestingly, a pathogenic role of NMO antibody (AQP4-IgG) in lesion development has been suggested in experimental models. This antibody-mediated damage occurs probably through complement-dependent astrocyte cytotoxicity and cytokine release, leading to oligodendrocyte death and demyelination (Zhang et al., 2011). A similar phenomenon has been recently described in MS. More than half of the patients displayed serum antibodies against a potassium channel expressed mainly by astrocytes, the KIR 4.1 (Srivastava et al., 2012), reinforcing the view that demyelination could, at least in part, result from primary damage in other cell types such as astrocytes.

Diffusible Molecules and Demyelination
Closely linked to the inflammatory infiltration in the CNS, several diffusible factors are possibly involved in the demyelination process. IFN-γ, a TH1-derived
cytokine, is expressed in MS lesions. Beside its well-known antiviral and proinflammatory action, overexpression of IFN-γ in the CNS could participate in demyelination. Transgenic overexpression of IFN-γ in the mouse by CNS oligodendrocytes led to chronic demyelination that may be severe (Corbin et al., 1987; Horwitz et al., 1997; Renno et al., 1998). The mechanism underlying this IFN-γ-mediated myelin injury may be due to induction of MHC expression in oligodendrocytes (Turnley et al., 1991; Horwitz et al., 1999). However, in EAE mice there is some contradictory data concerning the putative impact of IFN-γ on disease evolution (Sriram and Steiner, 2005). Moreover, a clinical study in MS patients has reported worsening of the disease in patients receiving IFN-γ (Panitch et al., 1987), although a link with increased demyelination has not been demonstrated.

TNF-α is the most comprehensively studied cytokine in both EAE and MS. Most TNF-α overexpressing transgenic animals showed spontaneous pathology, characterized by progressive demyelination and macrophage infiltration (Owens et al., 2001). The cytopathic action of TNF-α is dependent on signaling through the P55 TNF receptor (TNF receptor I) (Akassoglou et al., 1998). Nevertheless, by contrast to its potential cytopathic effect, experimental studies have shown that the second TNF receptor (P75 TNF receptor II) might exert a protective effect on oligodendrocytes and myelin (Arnett et al., 2001) and promote Treg function (Chen and Oppenheim, 2011). In MS, surprisingly, worsening of the disease has been reported in a clinical trial evaluating a neutralizing antibody directed against TNF-α (Lenercept Multiple Sclerosis Study Group, 1999), illustrating the complex interaction of TNF-α with the pathogenesis of lesions.

Despite the fact that many other cytokines and chemokines have been shown to participate in the inflammatory reaction, most of them do not interact directly with demyelination (Owens et al., 2001). In mice overexpressing interleukin (IL)-3 in astrocytes, however, demyelination associated with macrophage and microglial activation has been described (Campbell, 1998).

Several lines of evidence suggest that glutamate could also mediate injury to either the myelin or the oligodendrocyte in EAE and in MS. Glutamate is released in large quantities by activated immune cells, so that it could accumulate in lesions and trigger cell injury. Indeed, altered glutamate homeostasis with a high-level glutaminase expression near dystrophic axons, together with decreased expression of glutamate dehydrogenase, glutamine synthetase, and glutamate transporter by oligodendrocytes in MS lesions, could contribute to deleterious accumulation of glutamate in MS brain (Werner et al., 2001; Pitt et al., 2003). Such excess of glutamate is thought to mediate oligodendrocyte cell death through kainate and AMPA receptors expressed by the cell bodies (Matute, 1998; McDonald et al., 1998). It has also been suggested that glutamate could mediate calcium accumulation, process retraction, and myelin injury through NMDA receptors expressed by oligodendrocyte processes (Karadottir et al., 2005; Salter and Fern, 2005; Micu et al., 2006).

DEMYELINATION AS A CONSEQUENCE OF OLIGODENDROCYTE INJURY

In addition to the long-favored hypothesis suggesting that auto-reactive T cells are generated in the systemic compartment and access to the CNS where they persist and induce demyelination, it has been proposed that events within the CNS could trigger the MS disease process. In their subtype characterization of MS demyelinating lesions, Lucchinetti et al. (2000) already suggested that type III and IV lesions could correspond to a primary oligodendroglial dystrophy with subsequent inflammation. Especially in the type III lesions, the preferential loss of myelin-associated glycoprotein (MAG), together with oligodendrocyte nuclear condensation and fragmentation typical for apoptosis, suggests that the primary abnormality is intrinsic to oligodendrocytes. Interestingly, most of these cases had a very short disease duration, reinforcing the view that, at least in some cases, this subtype could represent the initial pathogenic process of the disease.

This hypothesis was illustrated by the observation of Barnett and Prineas (2004), suggesting that the earliest event in lesion formation might be a caspase-independent apoptosis of oligodendrocytes, which serves to recruit an initial innate (microglial) and a secondary adaptive (T-cell) immune response. In this study, oligodendrocyte cell death with features of apoptosis occurred prior to phagocytosis of myelin by macrophages, arguing against the long-held view that macrophages are the primary mediators of myelin destruction. The induction of a pathogenic immune reaction against white-matter antigens in response to a primary glial abnormality is a mechanism that has been reported in several types of leukodystrophy. For example, in X-linked adrenoleukodystrophy, the initial event in disease pathogenesis is induced by a primary mutation in a peroxisomal membrane protein (adrenoleukodystrophy protein: ALDP) with accumulation of very long-chain fatty acids in white-matter tracts of the CNS. Nevertheless, the most severe phase of the disease is related to the subsequent occurrence of inflammation (Berger et al., 2001). Moreover, CD8+ cytotoxic T lymphocytes are often tightly attached to oligodendrocytes in ALD tissues (Moser, 2004). Similarly, in Leber’s hereditary optic neuropathy, which is due to mitochondrial mutations, the evolution of the disease can be
influenced by an inflammatory reaction within the optic nerves or other white-matter areas (Kovacs et al., 2005).

Recent findings have suggested that, following a primary oligodendrocyte or myelin injury, local APCs could process myelin antigens and traffic from the CNS to secondary lymphoid organs, where they may induce or enhance an adaptive demyelinating immune reaction. This hypothesis was supported by the identification of trafficking antigens in the meninges and in the cervical lymph nodes (Fabriek et al., 2005; Kooi et al., 2009).

TARGETED ANTIGENS IN MYELIN

Diversity of putative antigens

Despite the fact that the antigen specificity of the T cells found in MS lesions is largely unknown, several candidate antigens, known to be capable of inducing EAE, have been proposed as possible targets for the immune reaction in MS. Such CNS antigen-specific T cells may be normal components of the immune system, but may cause demyelination once they have undergone peripheral activation (for review, see Bradl and Hohlfeld, 2003). However, to date, there is no proof that any of these autoantigens act as the antigenic target in MS. The most widely studied myelin antigens are MBP, proteolipid protein (PLP), and MOG. MBP is one of the most important myelin proteins in the CNS, and several MBP peptides are encephalitogenic in different animal strains for EAE. In humans, immunodominant peptides have also been identified, mostly in the middle section of the molecule (residues 83–102), but also in the N- and C-terminus (Ota et al., 1990). Interestingly, the importance of the middle region was further supported by the finding that it is recognized in the context of a number of HLA-DR molecules that are associated with MS (mainly HLA DRB1*1501) (Martin et al., 1991; Krosgsgard et al., 2000).

Support for a pathogenic role of MBP-reactive T lymphocytes in MS also comes from the results of a phase II clinical trial evaluating an altered peptide ligand of MBP. In this study, disease exacerbation in a small number of patients was associated with a strongly cross-reactive T-cell response against MBP 83–99 (Bielekova et al., 2000). The primary physiologic role of MBP is thought to be maintaining (by its positive charge) the proper compaction of the myelin sheath by juxtaposing the faces of the cytoplasmic leaflets of the oligodendrocyte membrane. Modifications of the MBP molecule by posttranslational events (e.g., methylation, deamidation, phosphorylation, deamination with conversion of arginines to citrullines) commonly occur and may modify the electric charge and, thus, reduce myelin stability (Ridsdale et al., 1997; Kim et al., 2003; Harauz et al., 2004). Accordingly, the lowest cationic form of MBP (named C8, with extensive deminination of arginyl residues) was found in elevated levels in patients with MS, and the proportion of arginine loss caused by deminination is higher in acute severe MS compared to more chronic MS (Moscarello et al., 1994, 2002; Wood et al., 1996). Supporting these observations are recent suggestions that a reduction in the net positive charge of MBP not only interferes with compact myelin assembly but also makes the immunodominant epitope of this protein more surface-exposed, hence more accessible to protease digestion or immune degradation (Musse et al., 2006).

Whereas MBP is by far the most investigated myelin antigen in both MS and EAE, other candidate antigens have gained increasing attention. PLP-specific clones have been isolated at various stages of MS (Correale et al., 1995) and elevated frequencies of PLP-specific T cells have been found in blood and CSF (Sun et al., 1991). Similarly, in addition to the high frequency and possible pathogenic role of anti-MOG antibodies on myelin (see above), a higher proportion of T cells derived from MS sera was found to react with MOG compared to controls (Kerlero de Rosbo et al., 1993). Moreover, several other potentially encephalitogenic myelin antigens, such as MAG, have also been suggested (Zhang et al., 1993), as have zβ-crystallin (van Noort et al., 1995), and transadolase-H (Banki et al., 1994). Devic’s disease is an example of our better understanding of disease pathways, as aquaporin 4 has been identified as the target of the (mostly humoral) immune response (Wingerchuk et al., 2007). More recently, neuronal adhesion molecules expressed at the nodal and paranodal junction have been suggested as potential targets of the immune response. These targets were identified using MS sera and a proteomic screen on a glycoprotein fraction isolated from human myelin by affinity chromatography (Mathey et al., 2007; see review by Desmazières et al., 2012).

These data, which need to be confirmed on a larger population of MS, are in line with studies in MS tissue showing abnormally large aggregates of the glial isoform of neurofascin at axoglial junctions located at the periphery of demyelinating lesions (Howell et al., 2006) and suggest that the axoglial junction might be an area of particular vulnerability of tissue damage. Along the same line of results was the recent identification in MS patients of frequent KIR 4.1 antibodies targeting mainly astrocytes (Srivastava et al., 2012), introducing astrocytes as potent actors in the demyelination process.

The difficulties in proving that a target antigen is responsible for the immune reaction in MS are not surprising considering the heterogeneity of the disease and the dynamic nature of the autoimmune response (Hohlfeld and Wekerle, 2004). For instance in demyelinating models, the immune response can spread to...
different antigens (Lehmann et al., 1993). Epitope spreading is characterized by a widening of the immune response from a single antigenic epitope to different epitopes, either on the same molecule (e.g., the intramolecular epitope spreading observed for PLP) or on other molecules. Interestingly, it has been shown in different demyelinating animal models that such epitope spreading could take place directly in the CNS. Thus, in EAE, naive T cells can directly gain access to the inflamed CNS and, once inside, dendritic cells may activate these T cells to initiate spreading (McMahon et al., 2005). However, regardless of how attractive the theory might be, the actual occurrence of epitope spreading in patients with MS has not been well documented.

Does viral-mediated autoimmunity contribute to demyelination in MS?

The possible involvement of viruses in the etiology of MS is still controversial despite much work in this area. A viral infection can influence demyelination by two main mechanisms. First, a viral infection may directly injure oligodendrocyte pathology, as seen in several animal models such as Theiler’s murine encephalomyelitis, JHM coronavirus (Lampert et al., 1973; Powell and Lampert, 1975; Lipton and Canto, 1976; Schlitt et al., 2003), and in progressive multifocal leukoencephalopathy. Despite the impressive number of viruses that have been suspected and investigated to date, however, none has ever been implicated as being causally related to the demyelination in MS.

Second, a viral infection may trigger an autoimmune reaction against myelin self antigens and, thus, cause subsequent demyelination, as described in postinfectious encephalomyelitis. Indeed, several such mechanisms are possible, including molecular mimicry, bystander activation, and epitope spreading (Grigoriadis and Hadjigeorgiou, 2006). The most popular of these is molecular mimicry, which originally referred to the presence of a sequence identity between microbe-derived peptides and certain self antigens of the host. For example, the self antigen PLP139–151 is identical to the peptide (HI574–586) derived from Haemophilus influenzae (Croxford et al., 2005). Subsequently, this concept has been extended to include a structural resemblance between peptide–MHC complexes rather than strict identity. One example of this is the human MBP-specific T-cell receptor that can recognize either a peptide derived from MBP bound to HLA-DR2b or a peptide derived the Epstein–Barr virus (EBV) bound to HLA-DR2a (Lang et al., 2002; Hohlfeld and Wekerle, 2004; Oldstone, 2005). This could illustrate one possible interaction between EBV and MS (another hypothesis mainly involves the influence of EBV on B-cell function or bystander effects), as EBV infection is quite universal among MS adult patients (Owens and Bennett, 2012).

Bystander activation relates to the non-specific activation of autoreactive T cells due to a direct pathogenic effect of the virus on the target organ. In this model, viral-induced CNS damage leads to the release of sequestered myelin antigens, activation of local inflammation, and finally, recruitment of autoreactive lymphocytes that activate and initiate an autoimmune injury to myelin (Horwitz et al., 1998, 1999).

Finally, epitope spreading has been well described for virus-induced demyelination following infection by Theiler’s murine encephalomyelitis, with a spreading of the immune response to different epitopes within the myelin peptide PLP (Miller et al., 1997; McMahon et al., 2005).

NEURONAL CHANGES INDUCED BY DEMYELINATION

Demyelination has important consequences for the axon, both from disturbed impulse conduction and from modification of axolemma and membrane components.

Modifications of the axonal influx

In conjunction with electrophysiologic recording, experimental focal demyelination by different chemical agents such as diphtheria toxin, ethidium bromide, and lysolecithin has been used to analyze axonal function after demyelination. An area of demyelination has been shown to produce conduction block at the site of the lesion (McDonald, 1963), with preserved conduction distally. Segmental demyelination triggers a series of adaptive responses by the axon, including changes in distribution of ion channels along the axolemma. These changes, which take 2–3 weeks to develop, may facilitate the restoration of conduction across the demyelinated segment (Smith et al., 1981). However, in this circumstance, conduction along demyelinated axons is no longer saltatory and fast but, rather, is continuous and slow (Smith et al., 1982). In other circumstances, conduction block may persist and such an outcome is favored by factors such as a large axon diameter (Bostock and Sears, 1978), a long length of demyelination, the absence of any glial ensheathment (Shrager and Rubinstein, 1990), and the presence of deleterious factors such as nitric oxide (Redford et al., 1997). In addition, demyelinated axons may also become more excitable and generate trains of ectopic impulses at the site of demyelination (Smith and McDonald, 1982). This neurophysiology is probably associated with the positive paroxysmal symptoms that are so characteristic of MS, such as tonic spasms, paroxysmal dysarthria and ataxia, paresthesia...
and pain. Demyelinated axons may also become active in response to mechanic deformations (Smith and Hall, 1980; Smith and McDonald, 1982), and this results in the occurrence of paroxysmal symptoms such as Lhermitte’s sign. In addition, electrical activity in one axon can excite activity in an adjacent axon. Such cross-excitation, termed ephaptic transmission, might result in transitory symptoms. However, although demonstrated between myelinated and normal axons in a dystrophic mutant mouse, it has yet to be proven in CNS demyelinated axons (Smith, 1994).

**Changes in axonal structure and molecular organization**

**Changes in axonal caliber**

In the early and active lesions, the axonal caliber changes at the site of the demyelinated internode. The axons in the demyelinated portions are generally thicker. This increased caliber has been linked to the fact that neurofilaments in these enlarged demyelinated axons become loosely packed, perhaps reflecting the increased permeability of demyelinated axolemma. In addition, axonal cytoskeletal proteins are modified. Notably the degree of phosphorylation of neurofilaments subunits decreases.

**Modifications of axonal surface molecules on demyelinated axons**

In chronic MS lesions, re-expression of the poly-sialated (PSA) form of the neural cell adhesion molecule (NCAM) has been reported (Charles et al., 2002). This adhesion molecule, which is widely expressed on neurons and glial cells during development, is downregulated in adult CNS where its expression is restricted to areas of permanent plasticity. In MS, PSA-NCAM is re-expressed on some demyelinated axons within the plaques. By contrast, it is undetectable on either myelinated axons in the periplaque region or in the normal-appearing white matter. Most (possibly all) axons that re-express PSA-NCAM contain dephosphorylated neurofilaments, most likely indicating that they are chronically demyelinated axons. These findings strongly suggest that PSA-NCAM re-expression is a local phenomenon, thought possibly to be triggered by modification of local intracellular calcium pool, through voltage-dependent calcium channels expressed by the denuded axon (Kornek et al., 2001). During development PSA-NCAM has been shown, both in *vitro* and *in vivo*, to regulate myelination negatively, and removing it from the axonal surface is necessary to initiate the process of myelination (Charles et al., 2000). Perhaps, therefore, by disrupting oligodendrocyte–axon interactions, the re-expression of this inhibitory adhesion molecule in chronically demyelinated axons contributes to the failure of myelin repair in MS (Charles et al., 2002).

**Modifications of the nodal and perinodal molecular organization**

The molecular organization of the nodes of Ranvier in myelinated fibers permits the rapid saltatory conduction of nerve impulses. The nodes of Ranvier are separated from the internode by two distinct domains of the axolemma, the paranodal axoglial junction and the juxtaparanodal region, which are characterized by the presence of specific protein complexes. Voltage-gated sodium channels (Na\textsubscript{v}), ankyrin G, NrCAM, and 186-kDa neurofascin are highly enriched at the node (Bennett and Lambert, 1999; Jenkins and Bennett, 2001). At the paranodes, myelin loops are anchored to axons through sepalate-like junctions characterized by the enrichment of paranodin/Caspr and glycosylphosphatidylinositol-anchored cell adhesion molecule contactin (Einheber et al., 1997; Menegoz et al., 1997; Rios et al., 2000). The juxtaparanodal region, just beyond the innermost paranodal junction, is enriched in Shaker-type potassium (K\textsubscript{v}) channels, in association with caspr2, a second member of the caspr family and the cell adhesion protein TAG-1 (Poliaik et al., 1999; Traka et al., 2002, 2003). Demyelination produces major modifications of the distribution of these nodal and perinodal constituents. The altered distribution of sodium channels is associated with modification in the subtype of these channels. Paranodal and juxtaparanodal axonal proteins are also profoundly modified.

**Modification of sodium channels during demyelination**

A redistribution of Na\textsubscript{v} channels along the naked axon has been reported in experimental models of demyelination and in MS lesions both by autoradiography and by immunohistochemistry (Moll et al., 1991; Noebels et al., 1991; Craner et al., 2004a, b; Coman et al., 2006). It remains unknown whether this change is due to a Na\textsubscript{v} channel synthesis or to a redistribution of Na\textsubscript{v} channels from nearby nodes into the demyelinated (previously internodal) membrane. In addition to this diffuse redistribution, few broad Na\textsubscript{v} channel aggregates can be detected on demyelinated axons in all MS lesions, which are threefold larger than Na\textsubscript{v} channel aggregates in the periplaque areas or in the normal tissue (Coman et al., 2006). These “loose” aggregates are often associated with a diffuse Na\textsubscript{v} channel distribution further down the same axon. They may represent remaining nodes, anchored by ankyrin G. Alternatively, they may correspond to the phi nodes, which are seen prior to functional
remyelination (Smith et al., 1982), and which, therefore, might be involved in the process of myelin repair.

**Modification of the Na+ channels phenotype during demyelination**

In addition to the diffuse distribution of Na+ channels along denuded axons, recent studies using either subtype-specific antibodies or molecular probes have begun to identify the Na+ channel isoforms expressed along demyelinated axons, in MS and in experimental models of demyelination. These studies suggest that specific channel isoforms are associated with distinct physiologic functions such as the restoration of conduction or the degeneration of axons.

Nine genes encode distinct voltage-gated Na channels (Na+, 1.1–Na+, 1.9), which differ in their amino acid sequences, their voltage dependences, and their kinetics. Within the normal adult CNS, Na+, 1.6 is the predominant sodium channel, and is clustered at the node of Ranvier. During development, Na+, 1.2 channels are expressed diffusely along the axon prior to myelination, and subsequently at immature nodes. This immature pattern is followed by a switch from Na+, 1.2 to Na+, 1.6 at mature nodes of Ranvier, by the time that myelination is complete.

Within MS active plaques, as in EAE, it has been reported that both the Na+, 1.6 and the Na+, 1.2 channel isoforms are expressed along demyelinated axons (Craner et al., 2004a, b; Waxman et al., 2004). Expression of the Na+, 1.6 isoform is mostly associated with β-amyloid precursor protein (βAPP), reflecting the dysfunction of axonal transport in damaged axons in the plaques. By contrast, the Na+, 1.2 isoform is associated with βAPP-negative (i.e., non-damaged) axons. The widespread distribution of Na+, 1.2 channels in uninjured axons is similar to the diffuse distribution of Na+, 1.2 channels along premyelinated axons, or on non-myelinated axons in adult CNS. Interestingly, these two isoforms differ in the currents they produce. The Na+, 1.2 channel isoform produces a less persistent Na+ current than does the Na+, 1.6 isoform. Perhaps the redistribution of Na+, 1.2 along naked axons might be an adaptive response supporting the conduction of action potentials in demyelinated axons. By contrast, the redistribution of Na+, 1.6 might contribute to axonal injury by inducing persistent sodium currents and triggering, thereby, a reversal of the Na+/Ca2+ exchange. If so, this mechanism might permit an influx of calcium that leads to axonal damage (Waxman et al., 2004). These potential mechanisms open important new therapeutic opportunities for neuroprotection using specific Na+ channel blockers.

In addition to altered expression of Na+, 1.2 and Na+, 1.6 along demyelinated axon in MS, studies in EAE have demonstrated increased expression of the Na+, 1.8 channel isoform within Purkinje cells of the cerebellum. Similar results have also been reported in MS patients who have experienced progressive cerebellar deficits (Black et al., 2000), suggesting that this channelopathy might contribute to cerebellar dysfunction in MS (Shields et al., 2012). The functional importance of this upregulated Na+, 1.8 expression, however, has not yet been determined.

**Redistribution of paranodal and juxtaparanodal axonal proteins along naked axons**

In contrast to the heterogeneous distribution of Na+ channels, axonal proteins expressed normally at the paranode (Caspr/paranodin) and at the juxtaparanode (Kv, channels and Capsr2) are diffusely distributed along the demyelinated internode (Wolswijk and Balesar, 2003; Coman et al., 2006) or enlarged (Howell et al., 2006). The data obtained in MS tissue are in agreement with experimental observations in dysmyelinating mutant animals (Dupree et al., 1999; Mathis et al., 2001; Arroyo et al., 2002). This suggests that axoglial junctions and glial contact are necessary for the maintenance of paranodin/caspr aggregation. Studies of the juxtaparanodal K+ channels and caspr 2 in dysmyelinating mutants have reported either mislocalization (expression at previously paranodal regions) or diffuse redistribution (Dupree et al., 1999; Boyle et al., 2001; Mathis et al., 2001; Poliak et al., 2001). It has been suggested that the mislocalization of the K+ channel may be an early event during the course of demyelination, which is followed by a diffuse redistribution in the setting of chronic demyelination.

In conclusion, CNS demyelination, which can be the consequence of multiple pathophysiologic mechanisms, induces major changes within the axon – some are adaptive and others are injurious. Denuded axons become particularly vulnerable, and chronic demyelination is clearly an important determinant of fixed axonal injury and loss in MS. In this respect, myelin repair not only has the potential to restore the rapid, saltatory conduction of nerve impulses, it also has the potential to play a major role in preventing secondary axonal degeneration.

**References**

Akassoglou K, Bauer J, Kassiotis G et al. (1998). Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 153: 801–813.

Archelos JJ, Hartung HP (2000). Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci 23: 317–327.
Arnett HA, Mason J, Marino M et al. (2001). TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 4: 1116–1122.

Arroyo EJ, Xu T, Grinspan J et al. (2002). Genetic dysmyelination alters the molecular architecture of the nodal region. J Neurosci 22: 1726–1737.

Babbe H, Roers A, Waisman A et al. (2000). Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192: 393–404.

Banki K, Colombo E, Sia F et al. (1994). Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis. J Exp Med 180: 1649–1663.

Barnett MH, Prineas JW (2004). Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 55: 458–468.

Barnett MH, Parratt JD, Cho ES et al. (2009). Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 65: 32–46.

Bennett V, Lambert S (1999). Physiological roles of axonal ankyrins in survival of premyelinated axons and localization of voltage-gated sodium channels. J Neurocytol 28: 303–318.

Berger J, Moser HW, Forss-Petter S (2001). Leukodystrophies: recent developments in genetics, molecular biology, pathogenesis and treatment. Curr Opin Neurol 14: 305–312.

Berger T, Rubner P, Schautzer F et al. (2003). Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349: 139–145.

Butovsky O, Landa G, Kunis G et al. (2006). Induction and blockage of oligodendrogenesis by differently activated microglia in an animal model of multiple sclerosis. J Clin Invest 116: 905–915.

Charles P, Hernandez MP, Stankoff B et al. (2000). Negative regulation of central nervous system myelination by polysialylated-neural cell adhesion molecule. Proc Natl Acad Sci U S A 97: 7585–7590.

Charles P, Tait S, Faivre-Sarrailh C et al. (2002). Neurofascin is a glial receptor for the paranodin/Caspr-contactin axonal complex at the axoglial junction. Curr Biol 12: 217–220.

Chen X, Oppenheim JJ (2011). The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4(+) FoxP3(+) regulatory T cells. Immunology 133: 426–433.

Coman I, Aigrot MS, Seilhean D et al. (2006). Nodal, parano-dal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis. Brain 129: 3186–3195.

Corbin JG, Kelly D, Rath EM et al. (1996). Targeted CNS regulation of central nervous system myelination by hypertrophic glycosylation, reactional gliosis, and abnormal cerebellar development. Mol Cell Neurosci 7: 354–370.

Correale J, McMillan M, McCarthy K et al. (1995). Isolation and characterization of autoreactive proteolipid protein-peptide specific T-cell clones from multiple sclerosis patients. Neurology 45: 1370–1378.

Craner MJ, Hains BC, Lo AC et al. (2004a). Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain 127: 294–303.

Craner MJ, Newcombe J, Black JA et al. (2004b). Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci U S A 101: 8168–8173, 25.

Croxford JL, Anger HA, Miller SD (2005). Viral delivery of an epitope from Haemophilus influenzae induces central nervous system autoimmune disease by molecular mimicry. J Immunol 174: 907–917.

David S, Lacroix S (2003). Molecular approaches to spinal cord repair. Annu Rev Neurosci 26: 411–440.

Desmazières A, Sol-Foulon N, Lubetzki C (2012). Changes at the nodal and perinodal axonal domains: a basis for multiple sclerosis pathology? Mult Scler 18: 133–137.

Disanto G, Morahan JM, Barnett MH et al. (2012). The evidence for a role of B cells in multiple sclerosis. Neurology 78: 823–832.

Dupree JL, Girault JA, Popko B (1999). Axo-glial interactions regulate the localization of axonal paranodal proteins. J Cell Biol 147: 1145–1152.

Einheber S, Zanazzi G, Ching W et al. (1997). The axonal membrane protein Caspr, a homologue of neurexin IV, is a component of the septate-like paranodal junctions that assemble during myelination. J Cell Biol 139: 1495–1506.

Fabriek BO, Zwemmer JN, Teunissen CE et al. (2005). In vivo detection of myelin proteins in cervical lymph nodes of MS
patients using ultrasound-guided fine-needle aspiration cytology. J Neuroimmunol 161: 190–194.

Gaertner S, de Graaf KL, Greve B et al. (2004). Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology 63: 2381–2383.

Genain CP, Cannella B, Hauser SL et al. (1999). Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 5: 170–175.

Greter M, Heppner FL, Lemos MP et al. (2005). Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 11: 328–334.

Grigoridiadis N, Hadjigeorgiou GM (2006). Virus-mediated autoimmune in Multiple Sclerosis. J Autoimmune Dis 3: 1.

Harauz G, Ishiyama N, Hill CM et al. (2004). Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis. Micron 35: 503–542.

Hauser SL, Bhan AK, Gilles F et al. (1986). Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 19: 578–587.

Hauser SL, Waubant E, Arnold DL et al. (2008). B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676–688.

Hofbberger R, Aboul-Enein F, Brueck W et al. (2004). Expression of major histocompatibility complex I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol 14: 43–50.

Hohlfeld R, Wekerle H (2004). Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA 101 (Suppl 2): 14599–14606.

Horwitz MS, Evans CF, McGavern DB et al. (1997). Primary demyelination in transgenic mice expressing interferon-gamma. Nat Med 3: 1037–1041.

Horwitz MS, Bradley LM, Harbertson J et al. (1998). Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 4: 781–785.

Horwitz MS, Evans CF, Klier PG et al. (1999). Detailed in vivo analysis of interferon-gamma induced major histocompatibility complex expression in the central nervous system: astrocytes fail to express major histocompatibility complex class I and II molecules. Lab Invest 79: 235–242.

Howell O, Palser A, Polito A et al. (2006). Disruption of neurofascin localization reveals early changes preceding demyelination and remyelination in multiple sclerosis. Brain 129: 3173–3185.

Huseby ES, Liggitt D, Brabb T et al. (2001). A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 194: 669–676.

Jacobsen M, Cepok S, Quak E et al. (2002). Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 125: 538–550.

Jenkins SM, Bennett V (2001). Ankyrin-G coordinates assembly of the spectrin-based membrane skeleton, voltage-gated sodium channels, and L1 CAMs at Purkinje neuron initial segments. J Cell Biol 155: 739–746.

Kappos L, Di L, Calabresi PA et al. (2011). Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378: 1779–187.

Karadottir R, Cavelier P, Bergersen LH et al. (2005). NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 438: 1162–1166.

Kerlero de Rosbo N, Miro R, Lees MB et al. (1993). Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 92: 2602–2608.

Kim JK, Mastronardi FG, Wood DD et al. (2003). Multiple sclerosis: an important role for post-translational modifications of myelin basic protein in pathogenesis. Mol Cell Proteomics 2: 453–462.

Kooi EJ, van Horssen J, Witte ME et al. (2009). Abundant extracellular myelin in the meninges of patients with multiple sclerosis. Neuropathol Appl Neurobiol 35: 283–295.

Kornek B, Storch MK, Bauer J et al. (2001). Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 124: 1114–1124.

Kotter MR, Zhao C, van Rooijen N et al. (2005). Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis 18: 166–175.

Kovacs GG, Hofbberger R, Majtenyi K et al. (2005). Neuropathology of white matter disease in Leber’s hereditary optic neuropathy. Brain 128: 35–41.

Krogsgaard M, Wucherpfennig KW, Cannella B et al. (2000). Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J Exp Med 191: 1395–1412.

Lalive PH, Menge T, Delarasse C et al. (2006). Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci USA 103: 2280–2285.

Lampasona V, Franciotta D, Furlan R et al. (2004). Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 62: 2092–2094.

Lampert PW, Sims JK, Kniazeff AJ (1973). Mechanism of demyelination in JHM virus encephalomyelitis. Electron microscopic studies. Acta Neuropathol (Berl) 24: 76–85.

Lang HL, Jacobsen H, Ikemizu S et al. (2002). A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 3: 940–943.

Lassmann H (2004). Recent neuropathological findings in MS – implications for diagnosis and therapy. J Neurol 251 (Suppl 4): 1IV–1V.

Lehmann PV, Sercarz EE, Forsthuber T et al. (1993). Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 14: 203–208.

Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999). TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53: 457–465.

Demyelination in Multiple Sclerosis 97
Linington C, Bradl M, Lassmann H et al. (1988). Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 130: 443–454.

Lipton HL, Canto MC (1976). Theiler’s virus-induced central nervous system disease in mice. UCLA Forum Med Sci 263–277.

Lucchinetti C, Bruck W, Parisi J et al. (2000). Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47: 707–717.

Mantegazza R, Cristaldini P, Bernasconi P et al. (2004). Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association. Int Immunol 16: 559–565.

Martin R, Howell MD, Jaraquemada D et al. (1991). A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J Exp Med 173: 19–24.

Mathey EK, Derfuss T, Storch MK et al. (2007). Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 204: 2363–2372.

Mathis C, Denisenko-Nehrbass N, Girault JA et al. (2001). Essential role of oligodendrocytes in the formation and maintenance of central nervous system nodal regions. Development 128: 4881–4890.

Matute C (1998). Characteristics of acute and chronic kainate excitotoxic damage to the optic nerve. Proc Natl Acad Sci U S A 95: 10229–10234.

McDonald WI (1963). The effects of experimental demyelination on conduction in peripheral nerve: a histological and electrophysiological study. I. Electrophysiological observations. Brain 86: 501–524.

McDonald JW, Althomsons SP, Hyrc KL et al. (1998). Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med 4: 291–297.

McMahon EJ, Bailey SL, Casteneda CV et al. (2005). Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 11: 335–339.

Menegoz M, Gaspar P, Le Bert M et al. (1997). Paranodin, a glycoprotein of neuronal paranodal membranes. Neuron 19: 319–331.

Micu I, Jiang Q, Coderre E et al. (2006). NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 439: 988–992.

Miller SD, Vanderlugt CL, Begolka WS et al. (1997). Nitric oxide donors and myelin-plasma membrane connections in JHM mouse hepatitis virus encephalomyelitis. Lab Invest 33: 440–445.

Prat A, Antel J (2005). Pathogenesis of multiple sclerosis. Curr Opin Neurol 18: 225–230.

Prineas JW, Graham JS (1981). Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol 10: 149–158.

Prinz M, Garbe F, Schmidt H et al. (2006). Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 116: 456–464.

Redwood LS, Altemus M, Leong YM et al. (2001). Lymphocyte responses to stress in postpartum women: relationship to vagal tone. Psychoneuroendocrinology 26: 241–251.

Renno T, Taupin V, Bourroniere L et al. (1998). Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE. Mol Cell Neurosci 12: 376–389.
Ridsdale RA, Beniac DR, Tompkins TA et al. (1997). Three-dimensional structure of myelin basic protein. II. Molecular modeling and considerations of predicted structures in multiple sclerosis. J Biol Chem 272: 4269–4275.

Rios JC, Melendez-Vasquez CV, Einheber S et al. (2000). Contactin-associated protein (Caspr) and contactin form a complex that is targeted to the paranodal junctions during myelination. J Neurosci 20: 8354–8364.

Salter MG, Fern R (2005). NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 438: 1167–1171.

Schlitt BP, Felrice M, Jelachich ML et al. (2003). Apoptotic cells, including macrophages, are prominent in Theiler’s virus-induced inflammatory, demyelinating lesions. J Virol 77: 4383–4388.

Segal BM, Constantinescu CS, Raychaudhuri A et al. (2008). Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 7: 796–804.

Shields SD, Cheng X, Gasser A et al. (2012). A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis. Ann Neurol 71: 186–194.

Shrager P, Rubinstein CT (1990). Optical measurement of conduction in single demyelinated axons. J Gen Physiol 95: 867–889.

Skulina C, Schmidt S, Dornmair K et al. (2000). Contactin-associated protein (Caspr) and contactin form a complex that is targeted to the paranodal junctions during myelination. J Neurosci 20: 8354–8364.

Smith KJ (1994). Conduction properties of central demyelinated and remyelinated axons, and their relation to symptom production in demyelinating disorders. Eye 8: 224–237.

Smith KJ, Hall SM (1980). Nerve conduction during peripheral demyelination and remyelination. J Neurol Sci 48: 201–219.

Smith KJ, McDonal WJ (1982). Spontaneous and evoked electrical discharges from a central demyelinating lesion. J Neurol Sci 55: 39–47.

Smith KJ, Blakemore WF, McDonald WI (1981). The restoration of conduction by central remyelination. Brain 104: 383–404.

Smith KJ, Bostock H, Hall SM (1982). Saltatory conduction precedes remyelination in axons demyelinated with lyso-phosphatidyl choline. J Neurol Sci 54: 13–31.

Sriram S, Steiner I (2005). Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 58: 939–945.

Srivasrava R, Aslam M, Kalluri SR et al. (2012). Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 367: 115–123.

Sun JB, Olsson T, Wang WZ et al. (1991). Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 21: 1461–1468.

Sun D, Whitaker JN, Huang Z et al. (2001). Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 166: 7579–7587.

Traka M, Dupree JL, Popko B et al. (2002). The neuronal adhesion protein TAG-1 is expressed by Schwann cells and oligodendrocytes and is localized to the juxtaparanodal region of myelinated fibers. J Neurosci 22: 3016–3024.

Traka M, Goutbroze L, Denisenko N et al. (2003). Association of TAG-1 with Caspr2 is essential for the molecular organization of juxtaparanodal regions of myelinated fibers. J Cell Biol 162: 1161–1172.

Traugott U, Reinherz EL, Raine CS (1983). Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science 219: 308–310.

Turnley AM, Miller JF, Bartlett PF (1991). Regulation of MHC molecules on MBP positive oligodendrocytes in mice by IFN-gamma and TNF-alpha. Neurosci Lett 123: 45–48.

van Noort JM, van Sechel AC, Bajramovic JJ et al. (1995). The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis, Nature 375: 798–801.

Walsch MJ, Tourtellotte WW (1986). Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med 163: 41–53.

Waxman SG, Craner MJ, Black JA (2004). Na+ channel expression along axons in multiple sclerosis and its models. Trends Pharmacol Sci 25: 584–591.

Werner P, Pitt D, Raine CS (2001). Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50: 169–180.

Wingerchuk DM, Lennon VA, Lucchinetti CF et al. (2007). Distribution of T cell subsets within active chronic lesions. Lancet Neurol 6: 805–815.

Wolswijk G, Balesar R (2003). Changes in the expression and localization of the paranodal protein Caspr on axons in chronic multiple sclerosis. Brain 126: 1638–1649.

Wood DD, Bilbao JM, O’Connors P et al. (1996). Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann Neurol 40: 18–24.

Zhang Y, Burger D, Saruhan G et al. (1993). The T-lymphocyte response against myelin-associated glycoprotein and myelin basic protein in patients with multiple sclerosis. Neurology 43: 403–407.

Zhang H, Bennett JL, Verkman AS (2011). Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immuno-pathogenic mechanisms. Ann Neurol 70: 943–954.